Your browser doesn't support javascript.
loading
Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga; Wang, QuanQiu; Xu, Rong; DiFeo, Analisa.
Affiliation
  • Belur Nagaraj A; Case Comprehensive Cancer Center, Cleveland, OH, USA; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55904, USA.
  • Joseph P; Case Comprehensive Cancer Center, Cleveland, OH, USA.
  • Kovalenko O; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Wang Q; Dept. of Population and Quantitative Health Sciences, Case Western Reserve University, USA.
  • Xu R; Dept. of Population and Quantitative Health Sciences, Case Western Reserve University, USA.
  • DiFeo A; Case Comprehensive Cancer Center, Cleveland, OH, USA; Department of Pathology and Department of Obstetrics and Gynecology, University of Michigan, USA. Electronic address: adifeo@med.umich.edu.
Gynecol Oncol ; 151(3): 525-532, 2018 12.
Article in En | MEDLINE | ID: mdl-30301560
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplastic Stem Cells / Dronedarone / Amiodarone / Anti-Arrhythmia Agents Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplastic Stem Cells / Dronedarone / Amiodarone / Anti-Arrhythmia Agents Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States